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Abstract Alterations in brain nitric oxide (NO)/cGMP
synthesis contribute to the pathogenesis of hepatic
encephalopathy (HE). An increased asymmetrically
dimethylated derivative of L-arginine (ADMA), an
endogenous inhibitor of NO synthases, was observed in
plasma of HE patients and animal models. It is not clear
whether changes in brain ADMA reflect its increased local
synthesis therefore affecting NO/cGMP pathway, or are a
consequence of its increased peripheral blood content. We
measured extracellular concentration of ADMA and sym-
metrically dimethylated isoform (SDMA) in the prefrontal
cortex of control and thioacetamide (TAA)-induced HE
rats. A contribution of locally synthesized dimethylargini-
nes (DMAs) in their extracellular level in the brain was
studied after direct infusion of the inhibitor of DMAs
synthesizing enzymes (PRMTs), S-adenosylhomocysteine
(AdoHcy, 2 mM), or the methyl donor, S-adenosylme-
thionine (AdoMet, 2 mM), via a microdialysis probe. Next,
we analyzed whether locally synthesized ADMA attains
physiological significance by determination of extracellular
cGMP. The expression of PRMT-1 was also examined.
Concentration of ADMA and SDMA, detected by positive
mode electrospray LC–DMS–MS/MS, was greatly
enhanced in TAA rats and was decreased (by 30 %) after
AdoHcy and AdoMet infusion. TAA-induced increase (by
40 %) in cGMP was unaffected after AdoHcy administra-
tion. The expression of PRMT-1 in TAA rat brain was
unaltered. The results suggest that (i) the TAA-induced
increase in extracellular DMAs may result from their
effective synthesis in the brain, and (ii) the excess of
extracellular ADMA does not translate into changes in the
extracellular cGMP concentration and implicate a minor
role in brain NO/cGMP pathway control.
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Introduction
Acute liver failure (ALF) is a clinical manifestation of
sudden and severe hepatic injury resulting from a variety of
causes (Felipo 2013). It may lead to impaired cerebral
function known as hepatic encephalopathy (HE) due to
accumulation of neurotoxic and neuroactive substances in
the brain (Butterworth 2003). The pathophysiological basis
of HE remains unclear; however, the generally accepted
view is that toxic effects of ammonia on astrocytes play a
key role (Albrecht and Jones 1999; Kosenko et al. 1997;
Shawcross et al. 2007). One of the key aspects of ammonia
toxicity is related to the alterations in brain nitric oxide
(NO) signaling (Felipo 2013). Ammonia evokes activation
of N-methyl-D-aspartate (NMDA) receptors and, in conse-
quence, changes NO and cyclic GMP (cGMP) synthesis. It
was repeatedly reported that this pathway is differently
regulated and depended on the type of HE and/or its stage.
In severe and acute HE, excessive brain glutamate release
leads to the increased stimulation of the NMDA receptors
resulting in NO release (Cauli et al. 2008) and cGMP
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accumulation (Hermenegildo et al. 2000; Hilgier et al.
2004). On the other hand, chronic HE is associated with the
reduced cGMP synthesis (ElMlili et al. 2010).
Dimethylarginines (asymmetric, ADMA and symmet-
ric, SDMA), L-arginine derivatives, are endogenous
modulators of NO synthesis (Teerlink et al. 2009).
ADMA is present in a high concentration in the brain and
is a major endogenous NO synthases (NOSs) inhibitor and
a competitive inhibitor of the cellular L-arginine (Arg)
uptake through cationic amino-acid transporters (CAT)
(Cooke 2000; Teerlink et al. 2009). SDMA may compete
with Arg for uptake to the cell, thus limiting substrate
availability for NOSs (Leiper and Vallance 1999).
Dimethylarginines are formed by the degradation of
methylated proteins (Cooke 2000; McDermott 1976) via
protein arginine methyltransferases (PRMTs)-dependent
transfer of the methyl group from S-adenosylmethionine
(AdoMet) to Arg thus forming methylated Arg and S-
adenosylhomocysteine (AdoHcy) that is subsequently
hydrolyzed to homocysteine (Clarke 1993). PRMT-1 is
the major enzyme that generates ADMA, whereas PRMT-
2 synthesizes SDMA (Bełtowski and Ke˛dra 2006). The
major ADMA-eliminating route involves an enzymatic
reaction catabolizing ADMA to citrulline and dimethy-
lamine through ubiquitously localized dimethylarginine
dimethylaminohydrolase (DDAH) (Nijveldt et al. 2003).
Of interest, transamination of ADMA to d-keto-d-(N,N-
dimethylguanidino) valeric acid by alanine-glyoxylate
aminotransferase 2, distributed throughout the brain, is an
additional metabolic pathway of ADMA removal (Abe
et al. 2014).
A significant correlation between the increased plasma
ADMA level and the degree of hepatic dysfunction has
been found in patients with cirrhosis (Bajaj et al. 2013;
Lluch et al. 2004, 2006; Richir et al. 2008), hepatitis
C-related chronic liver disease (Vizzutti et al. 2007), severe
acute alcoholic hepatitis (Mookerjee et al. 2007b), and
ALF (Mookerjee et al. 2007a). The concentration of cir-
culating ADMA seems to be regulated mainly by DDAH,
which catalyzes its degradation (Leiper et al. 1999).
Recently, Mookerjee (Mookerjee et al. 2015) reported a
decreased expression of DDAH-1 isoform in the liver of
cirrhotic patients. Moreover, in TAA-induced ALF in
rodents, an increase in plasma ADMA level was shown to
correlate with the reduced activity of DDAH in the liver
(Bekpinar et al. 2015; Develi-Is et al. 2013) and brain
tissue (Milewski et al. 2015). An increased ADMA content
in plasma and brain tissue have also been reported in rat
models of chronic cirrhosis (Balasubramaniyan et al. 2012;
Laleman et al. 2005; Mookerjee et al. 2015).
A majority of the above studies have been focused on
changes in peripheral tissues and/or in plasma. The con-
tribution of dimethylarginines to the dysregulation of the
NO/cGMP pathway in HE-affected brain remains obscure.
In terms of neurological and cognitive impairment
observed in HE patients, it is of interest to analyze in a
well-established TAA rat model reproducing cerebral
metabolic changes and symptoms of ALF, the synthesis of
dimethylarginines directly in the brain. The extracellular
space of the brain attained by microdialysis is the only
compartment cohabited by blood-derived and brain-derived
dimethylarginines and, as such, the only compartment in
which relative contributions of the two pools can be
assessed. Considering above, a novelty of the present study
is a determination of the extracellular concentration of
ADMA and SDMA in the brain of ALF rats. Physiological
significance of locally synthesized dimethylarginines was
analyzed by measurement of cGMP content extracellularly.
Therefore, the aim of this study was to investigate: (i) ex-
tracellular brain concentration of dimethylarginines after
infusion of the PRMT inhibitor S-adenosylhomocysteine or
the methyl donor S-adenosylmethionine via a microdialysis
probe; (ii) cGMP formation after S-adenosylhomocysteine
infusion; and (iii) PRMT-1 expression in control and
thioacetamide (TAA)-induced ALF rats.
Materials and Methods
Animals
The studies were conducted on male Sprague–Dawley rats
of initial body weight between 250 and 300 g kept under
standard laboratory conditions at room temperature (22 C)
under an artificial light/dark cycle (12/12 h), with free
access to standard laboratory food and tape water. All
procedures were conducted in accordance with the
National Institutes of Health Guidelines for the Care and
Use of Laboratory Animals and received a prior approval
from the Bioethics Commission of the Academy, as com-
pliant with Polish Law (of January 21, 2005). All efforts
were made to reduce the number of animals and to mini-
mize their suffering.
Chemicals
ADMA, SDMA, ADMA-D6, thioacetamide, S-adenosyl-
methionine, and S-adenosylhomocysteine were provided
by the Sigma-Aldrich Chemical Co. (Steinheim, Ger-
many); isoflurane was from Baxter (Warsaw, Poland);
HPLC grade ethanol (EtOH), HPLC grade formic acid,
gradient grade acetonitrile (ACN), and LC/MS grade
ACN from J.T. Baker (Deventer, The Netherlands) were
purchased from Witko. MQ Water was purified with
Millipore (Millipore, Bedford, MA, USA) MilliQ
instrument.
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Acute Liver Failure Model
ALF with cerebral metabolic changes and symptoms typ-
ical of acute HE was induced by three i.p. injections of
thioacetamide (TAA) (300 mg/kg b.w.) at 24-h intervals
(Hilgier and Olson 1994; Hilgier et al. 1996) and sacrificed
24 h after third injection. Control rats received sodium
saline solution (0.9 % NaCl).
Microdialysis of the Rat Prefrontal Cortex
Bilateral microdialysis of the prefrontal cortex was carried
out 24 h after the last TAA administration. The rats were
anesthetized with 5 % isoflurane in air within 2 min and
then maintained in anesthesia during the whole experiment
with a 2 % isoflurane–air mixture. The body temperature
was kept at 37.3 C by a heating pad controlled by a rectal
thermometer. The animals were fixed in a Stoelting
stereotaxic frame. Briefly, concentric microdialysis probes
(dialyzing membrane: diameter 0.5 mm; length 3 mm,
CMA 12 Elite, CMA Microdialysis, Stockholm, Sweden)
were implanted bilaterally into the prefrontal cerebral
cortex through a small hole in the skull (stereotaxic coor-
dinates according to the atlas of Paxinos and Watson
(1986) were as follow: A/P ? 3.0; L ?(-) 1.0; D/V -3.5).
The probes were perfused with artificial cerebrospinal fluid
(aCSF), pH 7.4, containing: 126 mM NaCl, 2.4 mM KCl,
1.1 mM CaCl2, 0.8 mM MgCl2, and 0.5 mM KH2PO4 at a
rate of 2.5 ll/min. Six fractions were collected every
40 min (0–240 min), starting 30 min after implantation of
the probe. For stimulation, 2 mM S-adenosylhomocysteine
(AdoHcy) or 2 mM, and methyl donor, S-adenosylme-
thionine (AdoMet) in a standard aCSF was infused com-
mencing at 80 min, for 40 min, where after the medium
was changed back to aCSF. A 2 mM concentration, as the
lowest effective dose of the stimulants, was chosen after
preliminary experiments conducted with 1, 2, and 5 mM
concentrations. After completion of the microdialysis, the
anesthetized rats were immediately sacrificed by decapi-
tation. Dialysates were stored at -80 C until further
procedures were applied.
Positive Mode Electrospray LC–DMS–MS/MS
The extracellular levels of ADMA and SDMA were ana-
lyzed using positive mode electrospray LC–DMS–MS/MS.
Sample Preparation
The sample (20 ll) was mixed with 80 ll of ADMA-D6
(IS) solution in EtOH (4 ng/ml). Solution was evaporated
to dryness under nitrogen, reconstituted with 45 ll of
ACN, and transferred to chromatographic vials.
Calibration curve was prepared using the same buffer as
for microdialysis. Eight calibration points were prepared in
the range from 0.33 to 40.7 ng/ml for ADMA and from 0.5
to 40 ng/ml for SDMA.
Sample Analysis
Samples were analyzed using Waters Xevo TQ-S triple
quadrupole mass spectrometer coupled with Waters
Acquity I-Class UPLC.
A 3-min HPLC method was set up on Waters HILIC
equipped with 1.7 lm 2.1 9 100 mm column with ther-
mostatic control at 70 C. Mobile phase A was composed
of 0.1 % FA in ACN, mobile phase B 0.1 % FA in MQ.
Linear gradient from 20 to 70 % of phase B was used
within 2.1 min with the flow rate of 0.65 ml/min. Injection
volume was 3 ll. Retention time for both ADMA and
SDMA was 0.81 min.
MS detector worked in ESI ionization in MRM mode.
Separation was started with setting up MRM transitions
that were highly specific for each compound. Using tran-
sitions 203.15[ 46.11 (collision energy 14) for ADMA
and 203.15[ 172.17 (collision energy 12) for SDMA, we
saw no crosstalk between signals of both compounds as it
was previously reported in literature (Martens-Lobenhoffer
et al. 2012; Zotti et al. 2008).
Monitored transmission for ADMA-D6 (IS) was
209.19[ 164.19 (collision energy 15).
MS parameters were capillary (kV) 3.00; cone
(V) 30.00; source offset (V) 40.0; source temperature (C)
150; desolvation temperature (C) 550; cone gas flow (L/
Hr-nitrogen) 150; desolvation gas flow (L/Hr-nitrogen)
1000; collision gas flow (ml/Min) 0.15; and Nebuliser gas
flow (Bar) 7.00.
Determination of cGMP in the Microdialysis
Tubes intended for cGMP analysis were coated with 5 ll of
4 mM EDTA. Samples of probes perfused with aCSF were
collected every 40 min in the period of 80–240 min of
perfusion, and 2 mM AdoHcy was infused for 40 min at
80 min, as indicated. Extracellular cGMP level was
determined with cGMP Enzyme Immunoassay Biotrak
(EIA) System (Amersham Biosciences) according to the
manufacturer’s protocol with modifications (Hilgier et al.
2009).
RNA Isolation and Real-Time PCR
Total RNA from the rat brain cortex was isolated using TRI
Reagent (Sigma-Aldrich, St. Louis, MO, USA), and then
1 lg was reverse transcribed using the high-capacity
cDNA reverse transcriptase kit (Applied Biosystems,
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USA). Real-time PCR was performed in 96-well plates
with the ABI 7500 apparatus (Applied Biosystems, War-
rington, UK) using the Applied Biosystems Taqman probe
assay—PRMT-1 (Rn 00821202), b-actin (Rn 00667869).
Each reaction contained 5 ll Taqman Universal PCR
Mastermix in a total volume of 10, and 1 ll cDNA was
added to the reaction. The real-time PCR reactions were
performed for 10 min at 95 C, followed by 40 cycles of
15 s at 95 C, and 1 min at 60 C. The results of the
analysis were calculated in relation to the b-actin product,
and results were presented according to an Equa-
tion (2-DDCt) that gives the amount of target, normalized to
an endogenous reference, and relative to a calibrator. Ct is
the threshold cycle for target amplification (Livak and
Schmittgen 2001).
Protein Isolation and Western Blot Analysis
Approximately 50 mg of rat brain cortex tissue were
homogenized in 5 volumes of Triton lysis buffer at 4 C
(20 mM Tris pH 6.8, 137 mM NaCl, 2 mM EDTA, 1 %
Triton X-100, 0.5 mM dithiothreitol, and 1 mM phenyl-
methylsulfonyl fluoride) containing Protease inhibitor
cocktail (Sigma-Aldrich, St. Louis, MO), and Phosphatase
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA).
The brain homogenate was centrifuged for 15 min at
12,0009g, 4 C. The supernatants were used for total
protein determination and Western blot analysis. Briefly,
30 lg of protein was boiled with gel sample buffer (Sigma-
Aldrich, St. Louis, MO, USA), separated on sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and
then transferred onto nitrocellulose membrane. Blots were
blocked with 5 % nonfat dry milk in Tris-buffered saline
Tween-20 buffer. Incubation with PRMT-1 (A33) antibody
(1:1000, Cell Signaling, USA) was done in Tris-buffered
saline Tween-20 buffer with 2.5 % nonfat dry milk at room
temperature for 0.5 h followed by 10-min incubation with
peroxidase-conjugated anti-rabbit antibodies (1:2500,
Sigma-Aldrich, St. Louis, MO, USA) for detection by
ClarityTM Western ECL Substrate (Bio-Rad, USA). The
first antibody was stripped off with 0.1 M glycine and pH
2.9, and the second incubation (1 h, 20–22 C) was per-
formed with an anti-GAPDH antibody (1:5000, Sigma-
Aldrich, Aldrich, St. Louis, MO, USA).
Statistical Analysis
Biochemical parameters were analyzed by a repeated
measures ANOVA with the post hoc Newman–Keuls test.
Real-time PCR and Western blot results were analyzed by
the Student’s t test. Values were expressed as the
mean ± SEM or as a % of control group. A significance
level of p\ 0.05 was considered to be statistically
significant. All statistical analyses were performed using
Statistica for Windows v. 8.0 (Statsoft. Inc., USA).
Results
The Extracellular Levels of Dimethylarginines
(ADMA and SDMA)
The basal extracellular levels of ADMA and SDMA in the
prefrontal cortex of control rats were 13.27 ± 1.77 and
9.17 ± 1.46 nM, respectively (Figs. 1, 2), and were
maintained at this level during 240 min of the microdial-
ysis (data not shown).
The Effect of 2 mM AdoHcy on ADMA and SDMA
Concentration
The intracerebral infusion of AdoHcy via a microdialysis probe
did not significantly affect ADMA concentration in control rats
albeit a decreasing tendency could be observed (Fig. 1a).
However, the TAA-evoked increase in ADMA concentration
(to 450 %, p\0.01) was reduced (by 25 %, p\0.01) after
AdoHcy infusion (Fig. 1a). The ANOVA for repeated mea-
sures revealed a significant effects of treatment, time, and a lack
of treatment 9 time interaction (F1,11 = 13.54, p\0.01;
F2,22 = 8.57, p\0.01, respectively).
On the other hand, the basal SDMA level was increased
(to 200 %, p\ 0.05) in TAA rats, whereas AdoHcy
decreased it significantly (by 20 %, p\ 0.05) (Fig. 1b). The
ANOVA for repeated measures revealed a significant effects
of treatment, time, and treatment 9 time interaction
(F1,11 = 15.11, p\ 0.01; F2,22 = 6.70, p\ 0.01,
F2,22 = 4.29, p\ 0.05, respectively).
The AdoHcy-evoked decrease in ADMA level was still
maintained in the 6th fraction (240 min of microdialysis,
2 h after stimulation), while at the same time point, the
SDMA level returned to its basal value in TAA rats
(Fig. 1b) which proves that observed decrease in
dimethylarginines concentration resulted from AdoHcy
infusion and not the nonspecific gradual reduction during
time course of dialysis procedure.
The Effect of 2 mM AdoMet on ADMA and SDMA
Concentration
Acute TAA administration resulted in a substantial
increase in the basal extracellular levels of ADMA (to
900 % p\ 0.001) when compared to control group. The
intracerebral infusion of AdoMet resulted in a tendency
toward an increase (by 30 %) in ADMA in control rats
(Fig. 2a), whereas ADMA concentration in TAA rats was
significantly decreased (by 30 %, p\ 0.001). The
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ANOVA for repeated measures revealed significant effects
of treatment, time, and treatment 9 time interaction
(F1,10 = 51.48, p\ 0.001; F2,20 = 8.57, p\ 0.01;
F2,20 = 17.02, p\ 0.001, respectively). Significant inter-
action indicates that AdoMet differently modulates ADMA
level in control and in TAA rats.
With regard to the symmetric methylated arginine
derivative, the basal SDMA level was increased (to 350 %,
p\ 0.01) in TAA rats, whereas AdoMet decreased it sig-
nificantly (by 30 %, p\ 0.001) (Fig. 2b). There was no
effect of stimulation in the control group. The ANOVA for
repeated measures revealed a significant effect of treat-
ment, time, and a lack of treatment 9 time interaction
(F1,10 = 21.83, p\ 0.001; F2,20 = 7.91, p\ 0.001,
respectively). Of note, the AdoMet-induced reduction in
extracellular ADMA concentration was observed in TAA
rats until the 6th fraction (240 min of microdialysis, 2 h
after stimulation), while SDMA returned to the basal value
(Fig. 2b).
The Effect of the 2 mM AdoHcy
on the Extracellular cGMP Level
The basal extracellular concentration of cGMP in control
rats was 7.25 ± 0.29 fmoles/100 ll (Fig. 3). TAA admin-
istration increased basal cGMP (to 142 %, p\ 0.05)
(Fig. 3). The ANOVA for repeated measures revealed a
significant effect of treatment (F1,11 = 17.74, p\ 0.01).
There was no statistically significant effect of stimulation
with AdoHcy.
Fig. 1 The extracellular levels of ADMA (a) and SDMA (b) in the
prefrontal cortex of control and TAA rats: the effect of intracortical
administration of exogenous AdoHcy (2 mM). The results are
presented as % of basal control level ± SEM, n = 6–7. Symbols
indicate significance of differences in the post hoc Newman–Keuls
test: *p\ 0.05, **p\ 0.01 versus control rats; #p\ 0.05, ##p\ 0.01
versus fraction 2 of TAA rats; DDDp\ 0.001 versus fraction 3 of TAA
rats
Fig. 2 The extracellular levels of ADMA (a) and SDMA (b) in the
prefrontal cortex of control and TAA rats: the effect of intracortical
administration of exogenous AdoMet (2 mM). The results are
presented as % of basal control level ± SEM, n = 6. Symbols
indicate significance of differences in the post hoc Newman–Keuls
test: **p\ 0.01, ***p\ 0.001 versus. control rats; #p\ 0.05,
###p\ 0.001 versus fraction 2 of TAA rats; DDp\ 0.01 versus
fraction 3 of TAA rats
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The Effect of ALF on PRMT-1 in the Rat Prefrontal
Cortex
The PRMT-1 mRNA expression (Fig. 4a) and PRMT-1
protein level (Fig. 4b) in the brain cortex did not statisti-
cally significantly differ between TAA and control rats.
Discussion
In the present study, we demonstrated an increase in the
extracellular levels of dimethylarginines, ADMA, and
SDMA in the prefrontal cortex of rats with TAA-induced
ALF. The elevated ADMA concentration was not accom-
panied by a change in PRMT-1 expression. Intracerebral
infusion of the PRMTs inhibitor AdoHcy or the methyl
group donor AdoMet affected ADMA and SDMA syn-
thesis in the rat brain. However, locally increased
dimethylarginines simultaneously did not affect elevated
extracellular level of cGMP in the prefrontal cortex of
TAA rats.
ADMA plasma level is increased both in acute and
chronic liver failure (see ‘‘Introduction’’ section). The
study of Balasubramaniyan (2012) assessed an increased
ADMA content in the brain homogenate of bile duct-li-
gated (BDL) rats using a semiquantitative method of
immunoblotting. Recently, our group has reported that a
moderate increase in ADMA brain tissue level correlated
with decreased DDAH activity in the acute rat TAA model
of HE (Milewski et al. 2015). The present study extends the
above observations by demonstrating an increase in the
extracellular levels of ADMA and SDMA in the brain
cortex. It is worth noting that ADMA concentration in the
cerebral tissue homogenate increased by 40 % (Milewski
et al. 2015), whereas in the present study, extracellular
level of ADMA was several times higher compared to
control group. Presumably, the excess of ADMA is con-
tinuously released from the cell into the extracellular space.
In the present study, we not analyzed an intracellular
ADMA level that can be 10- to 20-fold higher than in
plasma and reach *5 lM (Teerlink et al. 2009). Such
cellular ADMA concentration is highly above the IC50 for
NOSs and might inhibit NO generation tonically, although
this would depend also on the cellular concentration of
arginine. To our knowledge, the extracellular content of
both ADMA and SDMA in HE was not determined.
Fig. 3 The extracellular levels of cGMP in the prefrontal cortex of
control and TAA rats: effect of intracortical administration of
exogenous AdoHcy (2 mM). The results are the mean ± SEM,
n = 6–7. Symbols indicate significance of differences in the post hoc
Newman–Keuls test: *p\ 0.05, **p\ 0.01 versus control rats
Fig. 4 PRMT-1 mRNA (a) and protein (b) expression in the brain
cortex of control and TAA rats. Results are presented as the
mean ± SEM, n = 5–6
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ADMA is an endogenous competitive inhibitor of the
neuronal NOS (nNOS) (Leiper and Vallance 2006) and a
less potent inhibitor of its inducible isoform (Ueda et al.
2003). Therefore, the physiological concentration of
ADMA is beneficial to neuronal cells due to inhibition of
NO generation by nNOS and prevention of excitotoxic
injury. The physiological concentration of ADMA is
approximately 10-fold higher than that of other methy-
larginines, and therefore, ADMA seems to play a crucial
role in controlling NO bioavailability (Blackwell 2010).
Moreover, in vitro studies suggest that the ADMA syn-
thesizing enzyme, PRMT-1 is more active in physiological
conditions than the SDMA synthesizing enzyme, PRMT-2
(Lakowski and Frankel 2009), and dominant activity of
PRMT-1 seems to keep the other PRMTs in check (Dhar
et al. 2013).
In general, several mechanisms may lead to the accu-
mulation of dimethylarginines: an increased methylation of
proteins by PRMTs, augmented proteolysis and release of
preformed methylarginines, impaired renal excretion, and
(solely ADMA) impaired metabolism by DDAH
(Bełtowski and Ke˛dra 2006). Reduced DDAH protein
expression and increased PRMT-1 were observed in alco-
holic hepatitis livers (Mookerjee et al. 2007b), thus indi-
cating that the increase in ADMA may result from both the
decreased breakdown and/or increased production. How-
ever, the increased ADMA in plasma transported through
the blood–brain barrier (BBB) may increase its brain level
without any changes in brain dimethylarginine metabolism.
Therefore, we were looking for a direct evidence that
locally, brain metabolism of dimethylarginines is, at least
partially, involved in ADMA/SDMA changes observed in
HE. Using AdoHcy and AdoMet, we documented a local
modulation of dimethylarginine synthesis, reflected by
their extracellular level, both in control and TAA rats.
During methyl transfer, AdoMet is converted to
AdoHcy, which can subsequently be hydrolyzed to ade-
nosine and homocysteine through a reaction catalyzed by
AdoHcy hydrolase (Palmer and Abeles 1979). In excess,
AdoHcy is a potent competitive inhibitor of trans-methy-
lation reaction (Finkelstein 1990; Mato et al. 1997) and
may lead to decreased dimethylarginine level. Therefore,
the experiments with 2 mM AdoHcy infused locally via
microdialysis probe to the prefrontal cortex were per-
formed. In line with our assumption, AdoHcy decreased
both, ADMA and SDMA levels in TAA rats indicating
effective modulation of brain dimethylarginine synthesis.
In control rats, a tendency toward the decrease in ADMA
level was observed. The competitive inhibition of PRMT
reflected in decreased dimethylarginine level does not
require translation of newly synthesized proteins therefore
can be observed shortly after AdoHcy stimulation. More-
over, turnover of methylated proteins occurs at a high rate
(Teerlink 2005) thus formation of dimethylarginines should
be considered as a constant and fast process.
Direct infusion of AdoMet to the brain cortex of TAA
rats decreased extracellular concentration of dimethy-
larginines. The possible explanation of this phenomenon is
associated with a feedback inhibition of PRMT by
AdoHcy, formed from AdoMet upon trans-methylation
(Gibson et al. 1961). The intensity of this inhibition was
reflected by the diminished dimethylarginine levels, which
were also reduced after AdoHcy administration, what
supports the above explanation. Intracortical infusion of
AdoMet to TAA rat brain, in conditions of insufficient
amount of the substrate (Huang et al. 1999), may lead to
intensive methylation of many acceptors of methyl group
(Fontecave et al. 2004; Lu 2000) and formation of AdoHcy
(Finkelstein 1990; Mato et al. 1997). Therefore, the
removal of AdoHcy is critical step. AdoHcy is converted to
homocysteine and adenosine in a reversible reaction cat-
alyzed by AdoHcy hydrolase, and hydrolysis occurs only
after rapid product removal (Finkelstein 1990; Mato et al.
1997). Therefore, a strong feedback inhibition observed
exclusively in TAA rats suggests that these processes are
impaired in HE. A noticeable increase (*30 %) of
AdoHcy level in the brain cortex tissue of TAA rats con-
firmed this assumption (manuscript in preparation). The
hypothesis is also supported by the observation that in
control rats AdoMet did not reduce the levels of
dimethylarginines. In the present study, a significant
interaction between time and treatment indicates an
opposite modulation of ADMA level in control and TAA
rats by AdoMet. Similarly, AdoMet was effective only in
TAA rats, significantly reducing (by *30 %) extracellular
SDMA level increased by TAA.
On the other hand, the possibility that other nonspecific
effects of AdoMet besides the inhibition of PRMT activity
by excess of AdoHcy may contribute to the diminished
dimethylarginine levels cannot be excluded. AdoHcy apart
of inhibiting trans-methylation reaction may promote
inhibition of DDAH activity after its conversion to
homocysteine (Lentz et al. 2003) contributing to ADMA
accumulation. However, in our experiments such effect
was not observed. Summing up, the feedback inhibition of
PRMT enzyme by AdoHcy seems the most reliable
explanation of the observed decrease in ADMA
concentration.
In our study, the expression of PRMT-1 in the brain
cortex of TAA rats is not altered. However, PRMT-1
protein expression measured by immunoblotting does not
reflect an actual activity of this enzyme, which is regulated
by a number of factors, like PRMT-binding proteins or
posttranslational modifications (automethylation, phos-
phorylation, and deimination) (Bedford and Clarke 2009).
Therefore, a more comprehensive study would be of
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interest to provide a reliable conclusion regarding
dimethylarginine synthesizing enzyme under ALF
conditions.
It can be assumed that transport of dimethylarginines
through the BBB contributes to the observed increase in their
extracellular level in TAA rat brain. However, an immediate
30 % reduction of ADMA and SDMA level after AdoHcy or
AdoMet infusion proves the hypothesis that an increased
brain content of dimethylarginines resulted from the syn-
thesis in the brain. More effective decrease in dimethy-
larginine levels after AdoHcy and feedback inhibition of
their synthesis after AdoMet observed only in TAA rats may
indicate an increased activity of PRMT enzymes in ALF.
Furthermore, it should be noticed that our study supports the
view that PRMT-1 is the dominant enzyme among other
methyltransferases (Dhar et al. 2013). TAA administration
evoked a more pronounced increase in ADMA (4- to 9-fold)
than SDMA (2.5- to 3-fold) level. Moreover, decrease in the
extracellular SDMA level after AdoHcy was lower than that
of ADMA, furthermore, the effect of AdoHcy or AdoMet on
SDMA persisted for a shorter period of time. This observa-
tion indicates presumably different activity and inhibitor
affinity of PRMT-1 and PRMT-2 enzymes what is reflected
by distinct contribution of ADMA and SDMA to the
pathogenesis of HE.
In our study, the concentration of cGMP was measured
in the microdialysis, not in the tissue. However, since
diffusion of this molecule to the extracellular space is an
instant process, the obtained data do genuinely reflect the
activity of the NO/cGMP pathway in the brain tissue
(Fedele and Raiteri 1999). We investigated the physio-
logical significance of changes in cellular ADMA level
evoked by AdoHcy on the extracellular cGMP concentra-
tion. In contrast to AdoMet, a methyl donor, a nonspecific
reaction of methylation, is unlikely to occur (Fontecave
et al. 2004; Lu and Mato 2012). The basal extracellular
cGMP level was increased in the TAA rat cortex in line
with earlier results (Hermenegildo et al. 2000; Hilgier et al.
2004) demonstrating the activation of NO/cGMP pathway
in acute stage of HE. Why in our experimental setting
AdoHcy did not affect cGMP synthesis, despite the per-
sistent decrease in the extracellular ADMA level, seems to
stay unsolved. It should be repeated that ADMA plasma
and/or brain level is increased both in acute and chronic
liver failure (see ‘‘Introduction’’ section). In contrast, NO/
cGMP pathway is differently altered, depending on HE
severity (Felipo 2013). Therefore, translation of changes in
dimethylarginine contents into cGMP level may not be
direct. In the present study, for the first time, we manipu-
lated with the synthesis of dimethylarginines and investi-
gated its influence on cGMP content locally in the brain of
ALF rats. Other reports suggesting a direct link, between
increased plasma ADMA concentration and cognitive
impairment in TIPS patients or BDL rat model of HE
(Bajaj et al. 2013; Huang et al. 2010) relied on a correlative
assumption. Herein, we suggest that association between
extracellular ADMA and cGMP contents is unlikely,
especially in the studied model of ALF, when NO release is
to a greater extent controlled by excitotoxic mechanisms
resulting from overactivation of NMDA receptors.
Moreover, other possibilities of cerebral and/or systemic
consequences of elevated ADMA such as influencing brain
vascular constriction leading to the cerebral blood flow
(CBF) dysregulation, oxidative stress, and inflammation
should be considered. To this date, only circumstantial and
correlative evidence for a role of ADMA as a mediator of
selected processes in HE are available. Increased circulat-
ing ADMA levels, which inhibits NO synthesis, may be
associated primarily with endothelial dysfunction that
somehow can be translated on changes of CBF considered
as a causative and a predictive factor of overt HE. How-
ever, the exact mechanism by which direct effects of
ADMA in the brain are translated into CBF changes during
HE has not been elucidated in detail.
Summing up, our study demonstrates an increase of the
extracellular levels of dimethylarginines in the prefrontal
cortex of TAA rats. The obtained results prove that brain
synthesis of ADMA and SDMA is an effective process and
is altered under conditions of ALF. Moreover, the TAA-
induced increase in the extracellular cGMP level is not
directly affected by local modulation of dimethylarginine
synthesis.
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